Results 301 to 310 of about 2,202,582 (329)

Drug–drug interaction with statins

Expert Review of Clinical Pharmacology, 2008
3-hydroxy-3-methyl-glutaryl (HMG)-CoA reductase inhibitors (the so-called statins: atorvastatin, fluvastatin, pravastatin, lovastatin, rosuvastatin and simvastatin) are a well-established class of drugs in the treatment of hypercholesterolemia. Statin monotherapy is generally well tolerated, with a low frequency of adverse events.
A. Corsini, S. Bellosta
openaire   +2 more sources

Drug—Drug Interactions in the Elderly

Annals of Pharmacotherapy, 2002
OBJECTIVE: To detect the frequency of potential drug—drug interactions (DDIs) in an outpatient group of elderly people in 6 European countries, as well as to describe differences among countries. DATA SOURCES AND METHODS: Drug use data were collected from 1601 elderly persons living in 6 European countries.
Ingeborg K Björkman, Johan Fastbom, Ingrid K Schmidt, Cecilia B Bernsten, Cecilia B Bernsten, Ingeborg K Björkman, Margarida Caramona, Grainne Crealey, Bente Frøkjær, Erika Grünberger, Tove Gustafsson, Martin Henman, Hanne Herborg, Carmel Hughes, James C McElnay, Maeve Magner, Foppe van Mil, Marion Schaeffer, Sonia Silva, Birthe Søndergaard, Ian Sturgess, Dick Tromp, Lisa Vivero, Almut Winterstein   +23 more
openaire   +2 more sources

CARDIOVASCULAR DRUG-DRUG INTERACTIONS

Cardiology Clinics, 2001
The drug-drug interactions discussed in this article have either documented or suspected clinical relevance for patients with cardiovascular disease and the clinician involved in the care of these patients. Oftentimes, drug-drug interactions are difficult, if not impossible, to predict because of the high degree of interpatient variability in drug ...
J R, Anderson, J J, Nawarskas
openaire   +2 more sources

Drug-Drug Interactions with Antipsychotics

CNS Spectrums, 2007
Recognizing drug-drug interactions (DDIs) has become increasingly important as the country's demographics have aged, resulting in more complex medication regimens. Budnitz and colleagues highlighted the frequency of adverse drug reactions (ADRs) and the substantial morbidity that results.
openaire   +2 more sources

Avoiding Drug-Drug Interactions

Chemotherapy, 2009
<i>Background:</i> Drugs may be prescribed in combinations causing drug-drug interactions (DDI) and adverse drug reactions (ADR), resulting in hospital care. <i>Methods:</i> To provide prescribers of drug therapy with a better knowledge of individuals’ current drug therapy, governments have started to collect prescribing data ...
openaire   +2 more sources

Identification of Serious Drug–Drug Interactions: Results of the Partnership to Prevent Drug–Drug Interactions

Journal of the American Pharmacists Association, 2004
To develop a list of clinically important drug-drug interactions (DDIs) likely to be encountered in community and ambulatory pharmacy settings and detected by a computerized pharmacy system.Cross-sectional, one-time evaluation.United States in fall 2001.An expert panel comprising two physicians, two clinical pharmacists, and an expert on DDIs ...
Daniel C, Malone, Jacob, Abarca, Philip D, Hansten, Amy J, Grizzle, Edward P, Armstrong, Robin C, Van Bergen, Babette S, Duncan-Edgar, Steven L, Solomon, Richard B, Lipton   +8 more
openaire   +2 more sources

Six Patterns of Drug-Drug Interactions

Psychosomatics, 2003
The literature on pharmacokinetic drug-drug interactions usually focuses on various interactions relating to the cytochrome p450 system, phase II glucuronidation, and P-glycoprotein function. However, there has been relatively little examination of how the modes or patterns that govern these interactions can be systematically characterized to better ...
Scott C, Armstrong, Kelly L, Cozza, Neil B, Sandson   +2 more
openaire   +2 more sources

Contradictions in Contraindications for Drug-Drug Interactions

Annals of Pharmacotherapy, 2011
Health-care providers use computerized provider order entry as a component of the electronic medical record system in conjunction with clinical decision support. An important aspect of clinical decision support is screening of drug-drug interactions including contraindications in the labeling approved by the Food and Drug Administration.
Vishal S, Shah, Robert J, Weber, Milap C, Nahata   +2 more
openaire   +2 more sources

Drug–Drug Interactions in Headache Medicine

Headache: The Journal of Head and Face Pain, 2016
BackgroundThe main treatments in a majority of headache patients are pharmacologic therapies. As a result, it is imperative to have strong background in pharmacotherapy used to treat headaches in order to provide optimal therapy and avoid drug interactions.
Hossein, Ansari, Sanaz, Ziad
openaire   +2 more sources

Assessment of drug–drug interaction for silymarin

Toxicology in Vitro, 2008
Silymarin was assessed for drug-drug interaction by permeability studies with Caco-2 cells, for cytochrome P450 induction with human primary hepatocytes and for cytochrome P450 inhibition with human liver microsomes. Studies with Caco-2 cells revealed no interference of silymarin with the permeability of nifedipine. Silymarin did not induce cytochromes
Johannes, Doehmer, Bernhard, Tewes, Kai-Uwe, Klein, Kristin, Gritzko, Holger, Muschick, Ulrich, Mengs   +5 more
openaire   +2 more sources